XTL Biopharmaceuticals Ltd.

Legal Proceedings Report • May 4, 2006

C004	��� �� �� ������������� ��"�		2
Public	X T L BIOPHARMACEUTICALS LTD
	4312	Corporation no: 520039470
	Stock Exchange/Market: ��� �� ��
	1996
	352	Hasapir 3 , Nes Ziona 76100 , ,
	Tel: 08-9304444 , Fax: 08-9304445
	E.mail address: rcohen@xtlbio.com	Date of transmission: 04/05/2006
		Time of broadcast: 11:05 11:05:07
		Reference: 2006-02-052044

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate report on other matterDon't use this form if there is more adequate one

XTL Biopharmaceuticals Ltd. initiates patient dosing in Phase 1 clinical trial of XTL-2125, an oral, non-nucleoside polymerase inhibitor for the treatment of hepatitis C
Attached file 06-06InitiationoftrialXTL2125_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD
Date of revision of form structure: 30/03/2006
- - -
Name of the Signatory : Burgin Jonathan , , Position of Signatory in the reporting corporation: Chief Financial Officer
Hasapir Telephone: 08-9304440 , Facsimile: 08-9300659 , E-mail: jburgin@xtlbio.com